Multidrug-Resistant Bacteria on Critically Ill Patients with Sepsis at Hospital Admission: Risk Factors and Effects

Marcelo de Oliveira Maia1,2, Carlos Darwin Gomes da Silveira1,3,4, Maura Gomes5

  • 1Graduation Program in Health Sciences of School Health Sciences, Escola Superior de Ciências da Saúde (ESCS), Brasília, Federal District, Brazil.

Abstract

Insights

Multi-drug resistant organism (MDRO) infections significantly increase hospital mortality in critically ill sepsis patients. Early identification of MDRO risk factors is crucial, even for patients admitted within 48 hours to the ICU.

Area of Science:

  • Infectious Diseases
  • Critical Care Medicine
  • Epidemiology

Background:

  • Multi-drug resistant organisms (MDROs) pose a significant threat in intensive care units (ICUs).
  • Understanding the impact of MDRO infections on mortality in sepsis patients is critical for improving patient outcomes.

Purpose of the Study:

  • To evaluate the effect of multi-drug resistant organism (MDRO) infection on hospital mortality.
  • To identify risk factors associated with MDRO infection among critically ill sepsis patients at hospital admission.

Main Methods:

  • A prospective cohort study including adult sepsis patients admitted to an ICU in Brazil.
  • Data collection included patient characteristics, blood samples, and microbiological results.
  • Statistical analyses involved descriptive statistics, logistic regression, and propensity score matching.

Main Results:

  • MDROs were isolated in 9.8% of patients, with extended-spectrum beta-lactamase-producing Enterobacterales being most frequent.
  • Risk factors for MDRO infection included hypoxemic respiratory failure, low Glasgow Coma Score, neoplasm, and low hemoglobin.
  • MDRO infection at hospital admission was significantly associated with increased hospital mortality (OR 2.80).

Conclusions:

  • Multi-drug resistant organism (MDRO) infection is an independent risk factor for increased hospital mortality in critically ill sepsis patients.
  • Risk factors for MDRO should be assessed early, even in patients admitted to the ICU within 48 hours of hospital admission.

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
24
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
53
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
67
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
408
Antibiotic Selection00:57

Antibiotic Selection

Overview
54.9K
Defense Against Bacterial Pathogens01:31

Defense Against Bacterial Pathogens

The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.5K